Alkermes Restructures, Prioritizing CNS And Oncology And Cutting 160 Employees
The reorganization, which is expected to save $150m, will cement the company's transition from a drug delivery specialist to a drug developer, CEO Richard Pops said.
You may also be interested in...
Rodin is developing HDAC CoREST complex inhibitors for neurological conditions, with a lead candidate having completed Phase I testing. Alkermes will pay $100m upfront.
Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta
The latest drug development news and highlights from our US FDA Performance Tracker.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.